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Abstract
Alzheimer’s disease (AD) is associated with extensive alterations in grey matter microstruc-
ture, but our ability to quantify this in vivo is limited. Neurite orientation dispersion and
density imaging (NODDI) is a multi-shell diffusion MRI technique that estimates neuritic
microstructure in the form of orientation dispersion and neurite density indices (ODI/NDI).
Mean values for cortical thickness, ODI, and NDI were extracted from predefined regions of
interest in the cortical grey matter of 38 patients with young onset AD and 22 healthy con-
trols. Five cortical regions associated with early atrophy in AD (entorhinal cortex, inferior
temporal gyrus, middle temporal gyrus, fusiform gyrus, and precuneus) and one region rela-
tively spared from atrophy in AD (precentral gyrus) were investigated. ODI, NDI, and cortical
thickness values were compared between controls and patients for each region, and their
associations with MMSE score were assessed. NDI values of all regions were significantly
lower in patients. Cortical thickness measurements were significantly lower in patients in
regions associated with early atrophy in AD, but not in the precentral gyrus. Decreased ODI
was evident in patients in the inferior and middle temporal gyri, fusiform gyrus, and precu-
neus. The majority of AD-related decreases in cortical ODI and NDI persisted following
adjustment for cortical thickness, as well as each other. There was evidence in the patient
group that cortical NDI was associated with MMSE performance. These data suggest distinct
differences in cortical NDI and ODI occur in AD and these metrics provide pathologically rele-
vant information beyond that of cortical thinning.
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1 | INTRODUCTION
There is considerable interest in quantifying the neuropathological
alterations associated with Alzheimer’s disease (AD) using in vivo imag-
ing techniques. An extensive body of literature utilizing volumetric T1-
weighted MRI has highlighted that widespread cortical atrophy occurs
in multiple brain regions affected by AD pathology (Apostolova et al.,
2007; Becker et al., 2011; Bourgeat et al., 2010; Chetelat et al., 2012;
Dickerson et al., 2009, 2001; Fox et al., 2001; Frisoni, Prestia, Rasser,
Bonetti, & Thompson, 2009; Harper et al., 2017; Jack et al., 2015;
LaPoint et al., 2017; Lerch et al., 2004; Prestia et al., 2010; Singh et al.,
2006; Thompson et al., 2003; Whitwell et al., 2013, 2008; Xia et al.,
2017). Decreased dendritic arborization, loss of dendritic spines, and
loss of synapses have been observed in neuropathological studies of
AD and have been shown to be associated with cognitive deficits
(Baloyannis, Manolides, & Manolides, 2011; Davies, Mann, Sumpter, &
Yates, 1987; DeKosky and Scheff, 1990; Masliah, Terry, DeTeresa, &
Hansen, 1989; Scheff, Price, Schmitt, & Mufson, 2006; Scheff, Price,
Schmitt, DeKosky, & Mufson, 2007; Scheff, Price, Schmitt, Scheff, &
Mufson, 2011; Scheff and Price, 1993; Terry et al., 1991).
However, research into imaging techniques that can quantify AD-
related differences in cortical microstructure in vivo has been relatively
limited. Diffusion MRI, which measures the directionally-dependent dif-
fusion of water molecules, has been extensively applied to the study of
white matter in AD, and has also been proposed as a method of assess-
ing the microstructural properties of grey matter (Weston, Simpson,
Ryan, Ourselin, & Fox, 2015). Many diffusion MRI studies investigating
AD published thus far have used diffusion tensor imaging (DTI) analysis.
Differences in DTI metrics in the cortex have been associated with clini-
cally established AD (Rose, Janke PhD, & Chalk, 2008), conversion to
AD from mild cognitive impairment (Scola et al., 2010), cognitive decline
(Jacobs et al., 2013), cerebrospinal fluid (CSF) biomarkers of AD pathol-
ogy in cognitively normal individuals (Montal et al., 2017), and have
been used to differentiate dementia subtypes (Kantarci et al., 2010).
A limitation of the DTI model is that it can only assess diffusion of
water molecules across the entire voxel. An important development
has been multi-shell diffusion MRI techniques that allow more
advanced modeling of the diffusion signal, such as neurite orientation
dispersion and density imaging (NODDI) (Zhang, Schneider, Wheeler-
Kingshott, & Alexander, 2012); a clinically feasible approach that can
derive tissue-specific microstructural information from multiple com-
partments within a voxel. The NODDI model assumes that water mole-
cules in neuronal tissue can be considered within three separate
compartments: (a) free water, representing CSF; (b) restricted water,
representing neurites; and (c) hindered water, representing diffusion
within glial cells, neuronal cell bodies and the extracellular environment.
This enables estimation of the neurite density index (NDI), with values
ranging from 0 to 1 (higher values reflecting increased neurite density);
and orientation dispersion index (ODI), which provides information
regarding the extent of neurite dispersion (values of 0 equating to no
dispersion and values of 1 equating to full dispersion). This and related
modelling approaches in the context of grey matter provides informa-
tion regarding the structural organization of neuronal dendritic trees.
Furthermore, the capacity to model the fraction of free water reduces
the risk of partial volume effects from CSF contamination influencing
NODDI metrics, something which is not explicitly considered within
the DTI model (Zhang et al., 2012) and often significantly influence DTI
based studies of grey matter in AD (Henf, Grothe, Brueggan, Teipel, &
Dyrba, 2017; Jeon et al., 2012). Differences in cortical NODDI metrics
have been reported in ageing (Nazeri et al., 2015), Parkinson’s disease
(Kamagata et al., 2017), schizophrenia (Nazeri et al., 2016), multiple
sclerosis (Granberg et al., 2017), and transgenic murine models of AD
tauopathy (Colgan et al., 2016). To date, no studies have been
published assessing cortical microstructure using NODDI in human AD.
Within the wide clinical spectrum of AD, an interesting and rela-
tively understudied patient group is those with young onset AD
(YOAD—defined as symptom onset<65 years). Although less preva-
lent than in older age ranges, AD still represents the biggest cause of
dementia before the age of 65 (Harvey, Skelton-Robinson, & Rossor,
2003) and often poses a significant diagnostic challenge and is more
likely to present with nonamnestic phenotypes (Rossor, Fox, Mum-
mery, Schott, & Warren, 2010; Slattery et al., 2017). An advantage of
studying such patients is they often have fewer age-related co-morbid-
ities than patients with later onset disease, where co-existing patholo-
gies can confound analyses of brain structure. Studies specifically
focusing on grey matter atrophy in YOAD have revealed extensive
cortical atrophy compared to healthy controls (Cho et al., 2013; Frisoni
et al., 2007; Harper et al., 2017; Ishii et al., 2005; M€oller et al., 2013;
Ossenkoppele et al., 2015). Similarly, recent data from tau PET imaging
studies have provided evidence of diffuse neurofibrillary tangle deposi-
tion in the neocortex in YOAD (Ossenkoppele et al., 2016).
In this article, we applied a cross-sectional surface-based region of
interest (ROI) cortical analysis approach using NODDI metrics and cort-
ical thickness derived from T1-weighted images to a population of
patients with YOAD, as well as age-matched healthy controls to inves-
tigate the following hypotheses: (a) differences in NODDI metrics mir-
ror patterns of macroscopic atrophy in regions known to undergo early
AD-related pathological change, (b) NODDI metrics provide distinct
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information regarding AD-related pathology above and beyond meas-
ures of cortical thickness, (c) differences in NODDI metrics are evident
in a brain region vulnerable to AD pathology but known to be relatively
spared of atrophy (the precentral gyrus) (Albers et al., 2015; Braak
and Braak, 1991; Buchman and Bennett, 2011; Frisoni et al., 2007;
Horoupian and Wasserstein, 1999; Suva et al., 1999), implying NODDI
is a more sensitive marker of cortical pathology than macroscopic
measures, and (d) NODDI metrics are associated with a global score of
cognition.
2 | MATERIALS AND METHODS
2.1 | Participants
A total of 45 patients meeting consensus criteria for probable AD
(McKhann et al., 2011) with symptom onset <65 years were recruited
prospectively from 2013 to 2015 from a specialist cognitive disorders
clinic (Slattery et al., 2017). All participants underwent detailed clinical
assessment, which included the Mini–Mental State Examination(MMSE)
(Folstein, Folstein, & McHugh, 1975). Documentation of the age at
symptom onset and the presenting cognitive symptom were recorded
for all patients. Patients were classified as having a typical (McKhann
et al., 2011) or atypical AD (Tang-Wai et al., 2004) phenotype according
to published criteria. Twenty-eight of those patients were classified as
having typical AD (amnestic presentation), while 17 patients were classi-
fied as having atypical AD (14 of which had a visual symptom-led poste-
rior cortical atrophy phenotype). Twenty-four participants with no
history of cognitive concerns were recruited as healthy controls
matched for mean age and gender and were predominantly spouses of
the YOAD patients. Ethical approval was obtained from the National
Hospital for Neurology and Neurosurgery Research Ethics Committee
and written informed consent was obtained from all the participants.
2.2 | MRI acquisition
All participants were scanned on the same Siemens Magnetom Trio
(Siemens, Erlangen, Germany) 3 Tesla MRI scanner using a 32-channel
phased array receiver head coil. Sequences utilized for this analysis
included sagittal 3D MPRAGE T1-weighted volumetric MRI (TE/TI/
TR52.9/900/2,200 ms, matrix size 256 3 256 3 208, voxel size 1.13
1.1 3 1.1 mm3), B0 field mapping (TE1,2/TR54.92,7.38/688 ms, matrix
size 64 3 64 3 55, voxel size 3 3 3 3 3 mm3; total time59 min 23 s),
and a three shell diffusion sequence optimized for NODDI processing
(Slattery et al., 2017) (64, 32, and 8 diffusion-weighted directions at
b52,000, 700, and 300 s/mm2; 14 interleaved b50 images; 55 slices;
voxel size 2.5 3 2.5 3 2.5 mm; TE/TR592/7,000 ms; total time516
min 13 s). A twice-refocused spin echo was utilized to minimize distor-
tion effects from eddy-currents. All scans were visually assessed for
quality control purposes, based on coverage and movement artefact.
2.3 | Cortical reconstruction of structural imaging
Automated surface-based reconstruction of T1-weighted volumetric
images was performed using Freesurfer version 6.0 (http://surfer.nmr.
mgh.harvard.edu/). This procedure has been described in detail and
validated in previous publications (Dale, Fischl, & Sereno, 1999; Fischl
and Dale, 2000). Briefly, the image processing involves intensity
normalization, skull stripping, segmentation of white matter, and tessel-
lation of the grey/white matter boundary. This surface is then used as
the starting point for a deformable surface algorithm to find the grey
matter/white matter and grey matter/cerebrospinal fluid surfaces.
All cortical segmentations were visually inspected slice by slice for
accuracy (Figure 1, panel a).
2.4 | Cortical thickness estimation
Cortical thickness estimates were obtained using Freesurfer by calcu-
lating the mean distance between grey matter/white matter and grey
matter/cerebrospinal fluid surfaces at each vertex across the cortical
mantle (Dale et al., 1999; Fischl and Dale, 2000). These thickness meas-
ures were then mapped to the inflated surface of each participant’s
reconstructed brain.
2.5 | Diffusion-weighted MRI processing
Images were confirmed by visual inspection to have minimal eddy-
current distortion and were corrected for motion by rigidly registering
each diffusion-weighted image to the first b50 image from the
b52,000 s/mm2 series using FLIRT (Jenkinson, Bannister, Brady, &
Smith, 2002; Jenkinson and Smith, 2001). ODI and NDI maps were
estimated using the NODDI Matlab toolbox (http://www.nitrc.org/
projects/noddi_toolbox). The acquired field maps were then registered
to the first b50 and used to correct the ODI and NDI maps for EPI
distortion (Daga et al., 2014). To provide a mask for field map process-
ing a total intracranial mask (Malone et al., 2015) generated from
SPM12 (http://www.fil.ion.ucl.ac.uk/spm) segmentation was propa-
gated from the T1 to diffusion volumes by a union of direct affine
transformation and nonlinear transformation to provide maximal cover-
age before and after susceptibility correction. Structural T1 to diffusion
b50 and diffusion to field map magnitude registration was carried out
using Niftyreg (Modat et al., 2014) (Figure 1, panel b). All registrations
were visually inspected for accuracy. ODI and NDI values were then
sampled from the midpoint of the cortical ribbon (i.e. 50% of the corti-
cal thickness along the surface normal to the grey matter/white matter
surface) and subsequently projected to an inflated surface to create
ODI and NDI surface maps using the mri_vol2surf function in Freesur-
fer (Figure 1, panel c).
2.6 | Cortical ROIs
Mean cortical thickness, ODI, and NDI values across both hemispheres
were extracted for a number of a priori cortical ROIs from Freesurfer’s
gyral based Desikan parcellation using the mris_anatomical_stats func-
tion in Freesurfer (see panel d in Figure 1). Five of the ROIs were cho-
sen on the basis of being early sites of neuropathological change in AD.
These included four regions that comprise the Mayo Clinic cortical sig-
nature of AD (entorhinal cortex, inferior temporal gyrus, middle tempo-
ral gyrus, and fusiform gyrus) (Jack et al., 2015; Schwarz et al., 2016),
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all of which have been implicated to undergo grey matter atrophy at a
relatively early stage of AD (Braak and Braak, 1991; Dickerson et al.,
2011; Jack et al., 2017; Petersen et al., 2016; Weston et al., 2016) and
the precuneus, which has been reported to undergo more pronounced
atrophy in YOAD patients (Ishii et al., 2005; Karas et al., 2007; M€oller
et al., 2013). To investigate if cortical NODDI metrics are potentially a
more sensitive marker of AD pathology than cortical macrostructural
metrics, the precentral gyrus (primary motor cortex) was included as a
ROI. The precentral gyrus is relatively spared from atrophy in YOAD
(Frisoni et al., 2007), but there is evidence from neuropathological stud-
ies that the primary motor cortex is vulnerable to significant levels of
AD related pathology (Albers et al., 2015; Braak and Braak, 1991;
Buchman and Bennett, 2011; Horoupian and Wasserstein, 1999; Suva
et al., 1999).
2.7 | Exclusions
One patient with typical AD was found to have an autosomal dominant
genetic cause of dementia (Beck et al. 2014) and was excluded from
the analysis. YOAD patients with language-led or behavioral pheno-
types were not included in the analysis due to limited numbers (n52
and n51, respectively). One YOAD patient failed Freesurfer process-
ing. Three YOAD patients and two healthy control participants were
excluded on the basis of severe motion artefact identified during visual
inspection of the diffusion weighted MRI images.
2.8 | Statistical analysis
Sixty participants (38 YOAD and 22 controls) were included and Stata
version 14 was used for analysis. Demographics and clinical characteris-
tics were compared between each group. For continuous characteristics
two-sample t tests were used, or where there was a material departure
from a normal distribution, a Wilcoxon rank sum test was used. Categori-
cal characteristics were compared between groups using Fisher’s exact
test due to the relatively small numbers in each group. Unadjusted com-
parisons of cortical thickness, ODI and NDI between patient groups for
each ROI was performed using two-sample t tests, with Satterthwaite’s
approximation to allow for unequal variances. Given the large voxel size
of diffusion-weighted MRI images and the consequent increased risk of
contamination of the cortical ribbon with non-grey-matter voxels with
cortical thinning, linear regression comparing mean ODI and NDI values
between groups after adjustment for mean cortical thickness values in
each ROI (with robust standard errors to allow for heteroscedasticity)
was also performed. The NODDI model, by construction, treats NDI and
ODI as two independent measures that quantify distinct, but comple-
mentary aspects of microstructure. To investigate whether YOAD-
related differences in ODI or NDI occurred independent of each other
we performed linear regression models in each ROI (again with robust
FIGURE 1 Steps involved in surface-based region of interest
cortical analysis of NODDI maps. (a) Reconstruction of structural
imaging, (b) NODDI maps registered to structural imaging, (c) neo-
cortical midpoint values from ODI/NDI maps projected to inflated
surface, and (d) mean ODI/NDI values at each neocortical midpoint
extracted for each ROI from Desikan atlas. Key: GM5 grey matter;
WM5white matter; CSF5 cerebrospinal fluid; ODI5orientation
dispersion index; NDI5 neurite density index; ROI5 region of
interest [Color figure can be viewed at wileyonlinelibrary.com]
TABLE 1 Demographics, clinical, and genetic characteristics
HC (n5 22) YOAD (n538) p value
Age (years) 60.6 (5.6) 61.1 (4.9) .71a
% Female 54.5% 60.5% .79b
Age at onset (years) n/a 56.3 (4.4) n/a
Disease duration n/a 4.8 (2.6) n/a
MMSE score 29.5 (0.7) 21.2 (4.6) <.0001c
Years of education 16.5 (3.3) 15.5 (2.4) .15a
Note. Abbreviations: HC5healthy controls; YOAD5 young onset
Alzheimer’s disease; n5 number; SD5 standard deviation;
MMSE5Mini-Mental State Examination.
All data are mean (SD) unless stated otherwise.
aTwo-tailed t test.
bTwo-sided Fisher’s exact.
cWilcoxon rank sum.
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standard errors to allow for heteroscedasticity) where NDI and ODI
were corrected for each other, as well as cortical thickness. The associa-
tion between cortical thickness, ODI, and NDI values for each ROI with
MMSE score was assessed using Spearman’s correlation coefficient in
the YOAD group alone. To preserve a family-wise error rate of 5% to
detect differences in cortical thickness, ODI, and NDI, a threshold of
p< .008 for formal statistical significance was used after Bonferroni cor-
rection for comparison across the 6 ROIs.
3 | RESULTS
3.1 | Demographics and clinical characteristics
Basic demographic and clinical data are summarized in Table 1. There
were no significant differences in age, gender, or years of education
when comparing healthy controls with YOAD patients. As expected,
MMSE scores were significantly lower in YOAD patients compared to
controls. 27 patients had a typical amnestic presentation and 11 had an
atypical visual-led posterior cortical atrophy presentation. There were no
significant differences between typical and atypical AD patients in terms
of age, gender, age of symptom onset, disease duration, MMSE score, or
years of education (see Supporting Information).
3.2 | Direct comparisons of cortical thickness, ODI,
and NDI values in ROIs between patient groups
Mean values for cortical thickness, NDI, and ODI for each ROI and
their statistical comparisons by participant group are detailed in Table 2
and via boxplots in Figure 2. For all ROIs investigated, NDI was
significantly lower in YOAD patients compared to healthy controls
(p< .008—Bonferroni corrected threshold). Cortical thickness was sig-
nificantly lower in YOAD patients compared to healthy controls in the
ROIs associated with early atrophy in AD (entorhinal, inferior temporal,
middle temporal, fusiform, and precuneus) (p< .008—Bonferroni cor-
rected threshold), with a trend toward lower cortical thickness in
YOAD patients in the precentral ROI (p5 .01). ODI was lower in
YOAD patients compared to healthy controls in the ROIs associated
with early atrophy in AD (inferior temporal, middle temporal, fusiform,
and precuneus) (p< .008—Bonferroni corrected threshold), except the
entorhinal cortex where no statistically significant difference was
observed. There was also a trend toward lower ODI in YOAD patients
in the precentral ROI (p5 .026). There was no evidence for a difference
in NDI or ODI between the typical AD and atypical AD groups,
although there was evidence of reduced fusiform cortical thickness in
the atypical compared to typical YOAD patients (see Supporting
Information).
3.3 | NODDI metrics adjusted for cortical thickness
Differences in mean ODI and NDI values adjusted for mean cortical thick-
ness values in each ROI between healthy controls and YOAD are dis-
played in Table 3. Following adjustment for cortical thickness, NDI was
still significantly lower in YOAD patients compared to controls in the infe-
rior temporal, middle temporal, and precentral ROIs. There was also a
trend toward lower NDI in patients in the entorhinal and fusiform regions,
with no statistically significant differences observed in the precuneus. Fol-
lowing adjustment for cortical thickness mean ODI for all ROIs except the
entorhinal cortex was lower in YOAD patients compared to controls.
TABLE 2 Comparisons of cortical thickness, NDI, and ODI for each region of interest by participant group
Region of interest HC (n522) YOAD (n538) p value
Entorhinal Cortical thickness (mm) 3.48 (0.24) 2.92 (0.36) 2 3 1029**
NDI 0.359 (0.028) 0.267 (0.075) 1 3 1028**
ODI 0.494 (0.022) 0.490 (0.035) 0.6
Inferior temporal Cortical thickness (mm) 2.81 (0.11) 2.55 (0.19) 7 3 1029**
NDI 0.383 (0.013) 0.295 (0.062) 1 3 10210**
ODI 0.499 (0.024) 0.464 (0.035) 3 3 1025**
Middle temporal Cortical thickness (mm) 2.87 (0.12) 2.55 (0.21) 5 3 10210**
NDI 0.393 (0.014) 0.273 (0.064) 8 3 10213**
ODI 0.543 (0.019) 0.511 (0.020) 2 3 1027**
Fusiform Cortical thickness (mm) 2.76 (0.097) 2.41 (0.24) 5 3 10211**
NDI 0.389 (0.016) 0.309 (0.057) 1 3 10210**
ODI 0.525 (0.014) 0.476 (0.029) 7 3 10212**
Precuneus Cortical thickness (mm) 2.37 (0.10) 2.01 (0.17) 4 3 10214**
NDI 0.357 (0.025) 0.249 (0.068) 7 3 10212**
ODI 0.507 (0.013) 0.483 (0.030) 8 3 1025**
Precentral Cortical thickness (mm) 2.51 (0.16) 2.40 (0.19) 0.018*
NDI 0.346 (0.031) 0.276 (0.064) 4 3 1027**
ODI 0.498 (0.019) 0.484 (0.026) 0.026*
Note. Abbreviations: AD5Alzheimer’s disease; HC5 healthy controls; n5number; NDI5neurite density index, ODI5 orientation dispersion index;
SD5 standard deviation.
All data are mean (SD) unless stated otherwise.
*p< .05; **p< .008; Bonferroni corrected threshold: p5 .05 divided by 6 (total number of regions of interest).
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FIGURE 2 Box plots - cortical thickness, NDI, and ODI in healthy controls and young onset Alzheimer’s disease in a priori cortical regions-of-
interest (NDI5 neurite density index; ODI5orientation dispersion index): *p< .05 **p< .008. Bonferroni corrected threshold: p5 .05 divided
by 6 (total number of regions of interest) [Color figure can be viewed at wileyonlinelibrary.com]
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3.4 | ODI and NDI adjusted for each other
as well as cortical thickness
Comparisons between YOAD patients and healthy controls of mean
NDI adjusted for mean cortical thickness and mean ODI, as well as
mean ODI adjusted for mean cortical thickness and mean NDI, for each
region of interest are displayed in Table 4. Following adjustment for
mean cortical thickness and mean ODI, mean NDI was still significantly
lower in YOAD patients compared to controls in the inferior temporal,
middle temporal and precentral ROIs. There was also a trend toward
lower NDI in patients in the entorhinal, fusiform, and precuneus
regions. Following adjustment for cortical thickness and mean NDI,
mean ODI for all ROIs except the entorhinal cortex was lower in
YOAD patients compared to controls.
3.5 | Association with MMSE score
Association of mean NDI, ODI, and cortical thickness for each ROI with
MMSE scores in YOAD patients only is displayed in Table 5 and Figure 3.
There was evidence that lower MMSE was associated with lower NDI
and reduced cortical thickness with the strongest associations in the pre-
cuneus, inferior temporal, and middle temporal ROIs. No associations
were observed between MMSE and ROI values for ODI. No associations
were observed between MMSE and ROI values for cortical thickness,
NDI, or ODI in healthy controls (data not shown).
4 | DISCUSSION
We report evidence that there are widespread alterations in cortical
microstructure in YOAD, with reductions in NDI in YOAD patients
compared to healthy controls in all ROIs investigated (entorhinal, mid-
dle temporal, inferior temporal, fusiform, precuneus, and precentral)
TABLE 3 Comparisons of cortical thickness adjusted-NDI and corti-
cal thickness adjusted-ODI for each region of interest by participant
group
Region of
interest
Mean difference HC
vs YOAD (p value)
Entorhinal NDIadjusted for cortical thickness 20.048 (0.022
*)
ODIadjusted for cortical thickness 0.003 (0.73)
Inferior temporal NDIadjusted for cortical thickness 20.038 (0.002**)
ODIadjusted for cortical thickness 20.03 (0.006**)
Middle temporal NDIadjusted for cortical thickness 20.05 (0.0003**)
ODIadjusted for cortical thickness 20.032 (7 3 10
26**)
Fusiform NDIadjusted for cortical thickness 20.027 (0.011
*)
ODIadjusted for cortical thickness 20.03 (0.0003**)
Precuneus NDIadjusted for cortical thickness 20.026 (0.16)
ODIadjusted for cortical thickness 20.032 (0.0002**)
Precentral NDIadjusted for cortical thickness 20.055 (2 3 10
25**)
ODIadjusted for cortical thickness 20.019 (0.004**)
Note. Abbreviations: HC5 healthy controls; n5 number; NDI5neurite
density index; ODI5orientation dispersion index; SD5 standard
deviation; YOAD5Young onset Alzheimer’s disease.
*p< .05; **p< .008; Bonferroni corrected threshold: p5 .05 divided by 6
(total number of regions of interest).
TABLE 4 Comparisons between YOAD patients and healthy con-
trols of NDI adjusted for cortical thickness and ODI, as well as ODI
adjusted for cortical thickness and NDI, for each region of interest
Region of
interest
Mean difference HC
vs YOAD (p value)
Entorhinal NDIadjusted for cortical thickness & ODI 20.048 (0.022
*)
ODIadjusted for cortical thickness & NDI 0.003 (0.8)
Inferior
temporal
NDIadjusted for cortical thickness & ODI
ODIadjusted for cortical thickness & NDI
20.039 (0.003**)
20.031 (0.007**)
Middle
temporal
NDIadjusted for cortical thickness & ODI
ODIadjusted for cortical thickness & NDI
20.055 (0.001**)
20.034 (7 3 1025**)
Fusiform NDIadjusted for cortical thickness & ODI 20.013 (0.27)
ODIadjusted for cortical thickness & NDI 20.025 (0.001**)
Precuneus NDIadjusted for cortical thickness & ODI 20.042 (0.022
*)
ODIadjusted for cortical thickness & NDI 20.036 (0.0002**)
Precentral NDIadjusted for cortical thickness & ODI 20.076 (6 3 10
28**)
ODIadjusted for cortical thickness & NDI 20.032 (4 3 10
26**)
Note. Abbreviations: HC5 healthy controls; n5 number; NDI5neurite
density index; ODI5orientation dispersion index; SD5 standard
deviation; YOAD5Young onset Alzheimer’s disease.
*p< .05; **p< .008; Bonferroni corrected threshold: p5 .05 divided by 6
(total number of regions of interest).
TABLE 5 Association between region of interest metrics (cortical
thickness, NDI, and ODI with MMSE)
Region of
interest
Association with MMSE score
Spearman’s rho (p value)
All YOAD (n538)
Entorhinal Cortical thickness (mm) 0.36 (0.028*)
NDI 0.33 (0.045*)
ODI 20.15 (0.38)
Inferior
temporal
Cortical thickness (mm)
NDI
ODI
0.47 (0.003**)
0.49 (0.0019**)
20.08 (0.64)
Middle
temporal
Cortical thickness (mm)
NDI
ODI
0.49 (0.0018**)
0.57 (0.0002**)
20.11 (0.53)
Fusiform Cortical thickness (mm) 0.35 (0.029*)
NDI 0.33 (0.044*)
ODI 0.09 (0.58)
Precuneus Cortical thickness (mm) 0.60 (0.0001**)
NDI 0.50 (0.0013**)
ODI 20.20 (0.23)
Precentral Cortical thickness (mm) 0.13 (0.42)
NDI 0.32 (0.054)
ODI 20.076 (0.65)
Note. Abbreviations: AD5Alzheimer’s disease; HC5healthy controls;
n5number; NDI5neurite density index; ODI5orientation dispersion
index; YOAD5Young Onset Alzheimer’s disease.
*p< .05; **p< .008; Bonferroni corrected threshold: p5 .05 divided by 6
(total number of regions of interest).
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and reductions in ODI in YOAD patients compared to healthy controls
in inferior temporal, middle temporal, fusiform, and precuneus ROIs.
In ROIs associated with early atrophy in AD (entorhinal, inferior
temporal, middle temporal, fusiform, and precuneus) both mean
NODDI metrics (except entorhinal ODI) and cortical thickness differed
between healthy controls and those with YOAD. Associations between
cortical thickness and diffusion imaging metrics have been reported in
brain regions associated with atrophy in AD previously (Jacobs et al.,
2013). One potential interpretation of such results is that the decreases
in cortical thickness may result in decreases in diffusion metrics
because of partial volume effects rather than a purely biological associ-
ation (Henf et al., 2017; Jeon et al., 2012). This has been a longstanding
FIGURE 3 Scatter plots showing relationship between MMSE score (MMSE5mini mental state examination) and orientation dispersion
index (ODI)/neurite density index (NDI)/cortical thickness in YOAD patients only: *p< .05, **p< .008. Bonferroni corrected threshold:
p5 .05 divided by 6 (total number of regions of interest) [Color figure can be viewed at wileyonlinelibrary.com]
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criticism of diffusion MRI studies focusing on the cerebral cortex in
neurodegenerative disease (Weston et al., 2015), given the thin nature
of cortex and the limited spatial resolution of diffusion MRI acquisition
sequences (2.5 mm 3 2.5 mm 3 2.5 mm voxel size in this study) lead-
ing to increased risk of contamination with non-grey-matter voxels.
The NODDI model does attempt to account for this by modeling the
fraction of free water, with the aim of reducing the risk of partial vol-
ume effects from CSF. However, in the context of atrophy, there is still
a risk of partial volume effects from adjacent white matter, which is
not explicitly accounted for in the NODDI model. To explore the
impact of cortical thinning further, mean NDI and ODI values were also
adjusted for mean cortical thickness values in each ROI using regres-
sion models. After adjustment, the results still demonstrated statisti-
cally significant reductions in NDI and ODI when comparing YOAD
patients and healthy controls in the majority of the ROIs examined.
These results suggest that these microstructural metrics do provide
information regarding cortical structure above and beyond cortical
atrophy alone. Furthermore, it suggests that differences in NODDI
metrics are unlikely to be due to contamination from non-grey-matter
voxels. Findings in the aforementioned study by Nazeri et al. (2015)
describing ODI associations with increasing age also survived adjust-
ment for cortical thickness, providing further evidence that NODDI
metrics provide information beyond cortical macrostructure. The differ-
ence in precuneus NDI between YOAD patients and controls did not
survive adjustment for cortical thickness, although differences in ODI
did. The precuneus is one of the earliest brain regions to undergo vol-
ume loss in the course of YOAD (Ishii et al., 2005; Karas et al., 2007;
M€oller et al., 2013) and the patients included in this study all had estab-
lished disease. This finding is consistent therefore with the hypothesis
that whilst neurite loss may be an early feature of the disease, by the
time the disease becomes more advanced the likely inherent patho-
physiological relationship between NDI and cortical thickness becomes
more apparent. As discussed previously, it is however still possible that
cortical NDI is more susceptible than ODI to partial volume effects
from adjacent subcortical white matter.
We also report evidence that the majority of YOAD-related differ-
ences in ODI and NDI survive correction for each other, as well as cort-
ical thickness. The NODDI model (Zhang et al., 2012) proposes that
ODI estimates neurite dispersion, which in the context of grey matter
may reflect the degree of complexity of dendritic trees, while NDI is an
estimate of neurite density. Although, this requires histopathological
confirmation, these data support the notion that ODI and NDI provide
estimates of distinct microstructural properties, and they may be differ-
entially affected in YOAD.
It is interesting that there was significantly decreased NDI in the
precentral gyrus in YOAD patients compared to healthy controls, while
there was only weak evidence that these groups differed on a measure
of cortical macrostructure (cortical thickness). This is a region that is rel-
atively spared from atrophy in YOAD (Frisoni et al., 2007), however
there is evidence from neuropathological studies that it can be is a site
of AD-related pathology (Albers et al., 2015; Braak and Braak, 1991;
Buchman and Bennett, 2011; Horoupian and Wasserstein, 1999; Suva
et al., 1999). Although limited by its cross-sectional nature these data
raise the possibility that such decreases in NDI may precede macro-
scopically detectable differences in cortical structure and may be a
more sensitive marker of AD pathology.
We report evidence that lower NDI values in the precuneus, infe-
rior temporal, and middle temporal were associated with a lower global
score of cognition, in the form of MMSE, and may provide information
regarding disease severity. The capacity of cortical NODDI to provide
information regarding cognitive status is further supported by the fact
that associations between cortical differences in NODDI metrics and
cognition have also been demonstrated by Nazeri and colleagues in the
context of normal ageing (Nazeri et al., 2015) and major psychotic dis-
orders (Nazeri et al., 2016).
Colgan et al have published evidence that murine models of AD
tau pathology (rTg4510 transgenic mice) have lower cortical ODI com-
pared to wild type mice but increased cortical NDI. Increased cortical
NDI was also associated with an increased percentage of tau immuno-
reactivity (Colgan et al., 2016). The increases in NDI are discordant
with our data, which demonstrated consistent decreases in NDI in AD
patients. However, the mean symptom duration of YOAD patients in
this study was 4.8 years, which according to hypothetical models of
pathophysiological change in AD is likely to be decades after initial
deposition of hyperphosphorylated tau (Jack et al., 2010, 2013, 2017)
making direct comparison to such mouse models difficult. There is evi-
dence from human imaging studies suggesting that apparently paradox-
ical increases in grey matter volume and cortical thickness may occur in
the early stages of AD before a phase of accelerated atrophy (Chetelat
et al., 2010; Fortea et al., 2010, 2011, 2014; Montal et al., 2017;
Pegueroles et al., 2017). It is possible such nonlinear relationships may
occur in microstructural properties, but further studies are required to
fully elucidate these relationships. In particular, relating measurements
of cortical grey matter microstructure with data from in vivo PET radio-
tracers of beta-amyloid (Clark et al., 2011; Joshi et al., 2012; Klunk
et al., 2004) and tau deposition (Marquie et al., 2015) may be helpful to
delineate this relationship more precisely.
YOAD is notable for the degree of phenotypic heterogeneity and
our dataset did include a small number of patients (n511) with an
atypical, visual-led presentation consistent with a clinical diagnosis of
posterior cortical atrophy. No clear differences in ODI or NDI were
noted when comparing typical and atypical phenotypes in the ROIs
chosen for the purpose of this analysis. Previous larger scale analyses
have revealed differences in cortical macrostructure (Lehmann et al.,
2011) between typical AD and posterior cortical atrophy. In addition to
the small sample size, the lack of difference between phenotypes in
this analysis may also reflect the fact that the patients included were at
a relatively late stage of the disease and that differences in these
potentially more sensitive microstructural metrics were well established
in both phenotypes at this time point.
Limitations of this study include the fact that five participants
were excluded due to diffusion imaging movement artefacts (as well as
one participant failing Freesurfer processing). Furthermore, there was a
sole focus on AD patients with a young onset and replication in those
with later onset AD will be required in the future to further validate
the findings of this study. Furthermore, there is currently limited
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histopathological evidence to specifically validate NODDI metrics in
human cortical grey matter. However, NODDI-derived indices have
been shown to closely correlate with histological counterparts on post-
mortem examination in the context of multiple sclerosis spinal cord
lesions (Grussu et al., 2017). In addition, some discrepancies between
the NODDI model and emerging multi-shell diffusion techniques that
utilize linear and spherical tensor encoding (as opposed to the single
diffusion encoding approach of NODDI) have been reported (Lampinen
et al., 2017). Refinement of multi-shell diffusion analysis techniques is
an important avenue of research and may enable further insights into
grey matter microstructure in AD in the future.
Compared to the other ROIs, there was weaker evidence for sig-
nificant AD-related differences in NODDI metrics in the entorhinal cor-
tex. This may reflect the fact that precise localization of this
comparatively small region is difficult and combined with relatively
large voxels used in diffusion MRI make it more prone to noise. A fur-
ther limitation is the study’s cross-sectional nature and longitudinal
datasets comprising participants at different stages of the AD patholog-
ical continuum (including presymptomatic cohorts) will be required to
further tease out the temporal progression of cortical microstructural
change in AD. Another focus for future research, as previously high-
lighted, would be to investigate associations between cortical micro-
structure and neuroimaging modalities that quantify other pathological
processes in AD such as: beta-amyloid (Clark et al., 2011; Joshi et al.,
2012; Klunk et al., 2004) and tau deposition (Marquie et al., 2015), as
well as neuroinflammation (Fan, Brooks, Okello, & Edison, 2017) and
cerebrovascular disease (Sudre, Cardoso, & Ourselin, 2017) to further
disentangle the key pathological drivers of alterations in cortical
microstructure.
5 | CONCLUSIONS
These data provide in vivo evidence of differences in the NODDI den-
sity and dispersion indices of neurites in the cortex of YOAD patients
compared to age-match controls, which persisted in the majority of
ROIs following adjustment for cortical thickness. Differences in NDI
were present in brain regions known to undergo early atrophy in AD,
but also in a region typically spared of significant atrophy (precentral
gyrus). Furthermore, there was also evidence that cortical NDI was
associated with MMSE performance. These data suggest cortical
NODDI metrics provide information regarding AD-related pathology
above and beyond that of cortical thinning alone and support the
potential utility of cortical NODDI metrics as sensitive biomarkers of
cortical pathology in AD.
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